ClinicalTrials.gg
CompletedNCT03255512VISORUpdated Dec 29, 2021

Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients

A Phase 1 interventional study of Vericiguat (BAY1021189) and Placebo in Coronary Artery Disease, sponsored by Bayer. Completed at 6 sites in Germany. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-12-29.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Coronary Artery Disease by Bayer — 1 open to participants now, 1 under way, none of them phase 3. Coronary Artery Disease · Bayer.

Started
2017
the only one that year
Phase 1
4 of 14
1 open now
Registered
7th of 14
by date

Among the 14 studies in Coronary Artery Disease by Bayer, this one is the only one that started in 2017, is one of 4 in phase 1, and was the 7th registered.

Coronary Artery Disease

4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 14 studies in Coronary Artery Disease by Bayer is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Coronary Artery Disease by Bayer, or all of them as a file.
02

Study summary

This study is intended to investigate the pharmacodynamic drug-drug interaction as well as the safety and tolerability of isosorbite mononitrate and vericiguat in patients with stable coronary artery disease.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with stable CAD defined by

  • coronary artery stenosis in any of the 3 main coronary vessels > 50% documented by coronary angiography within last 36 months
  • or history of myocardial infarction
  • Age: 30 to 80 years (inclusive) at the first screening examination
  • (BMI): above/equal 18.0 and below/equal 36.0 kg / m²

Exclusion criteria

Exclusion Criteria:

  • Intervention e.g. revascularization by percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) during the last 3 months
  • Progressive angina with symptoms of worsening of angina within the \< 3 months prior to the first screening examination
  • History of recent (\< 6 months prior to the first screening examination) myocardial infarction or unstable angina
  • Symptomatic carotid stenosis, or or stroke within 3 months prior to the first screening examination or patients with stroke at more than 3 months prior to the first screening examination with significant residual neurologic involvement
  • Insulin dependent diabetes mellitus
  • cardiac ischemia at screening
  • Clinical significant persistent ischemia, which should be ruled out by clinical judgment of the investigator, based on medical history, available clinical data e.g. past angiograms or preexisting or current exercise testing with any imaging technique (e.g. dobutamine stress echocardiography, adenosine or dobutamine stress cardiac magnetic resonance imaging (CMR), scinthigraphy or exercise )
  • Atrial fibrillation, pacemaker, defibrillator, atrial ventricular (AV)-block II and III
  • Systolic blood pressure below 110 or above 160 mmHg at first screening visit
  • Diastolic blood pressure above 100 mmHg at first screening visit
  • Heart rate below 50 or above 100 beats / min (taken from ECG measurement) at first screening visit
  • Estimated (eGFR) \< 30 mL/min/1.73m*2 at first screening visit
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Vericiguat + isosorbite mononitrate

    Subjects received Isosorbide mononitrate (ISMN) up-titration with 30 mg / 60 mg, about 7 days each,prior to start of vericiguat administration. Then subjects received 2.5 mg vericiguat for about 14 days, followed by 5 mg vericiguat for about 14 days, followed by 10 mg vericiguat for about 14 days together 60 mg ISMN od on each day of vericiguat administration, taken 1 hour prior to vericiguat (in-house days) or together with vericiguat (out-patient days).

    Drug: Vericiguat (BAY1021189) · Drug: Isosorbide mononitrate (ISMN)

  • Placebo comparator
    Placebo + isosorbite mononitrate

    Subjects received Isosorbide mononitrate (ISMN) up-titration with 30 mg / 60 mg, about 7 days each, prior to start of placebo administration. Then subjects received placebo matching 2.5 mg vericiguat for about 14 days, followed by placebo matching 5 mg vericiguat for about 14 days, followed by placebo matching 10 mg vericiguat for about 14 days together 60 mg ISMN od on each day of placebo administration, taken 1 hour prior to placebo (in-house days) or together with placebo (out-patient days).

    Drug: Placebo · Drug: Isosorbide mononitrate (ISMN)

Interventions

06

What researchers measure

Primary outcomes

  1. Blood pressure

    Regular measurements of blood pressure after a vericiguat administration on the first and on the last days of each dose step of vericiguat, and on the first days of ISMN up-titration.

    Time frame: Up to 8 weeks

  2. Heart rate

    Regular measurements heart rate after a vericiguat administration on the first and on the last days of each dose step of vericiguat, and on the first days of ISMN up-titration.

    Time frame: Up to 8 weeks

Secondary outcomes

  1. Number of participants with adverse events

    Time frame: Up to 9 weeks

07

Study locations

6 sites
  • Universitätsherzzentrum Freiburg - Bad Krozingen
    Bad Krozingen, Baden-Württemberg 79189, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, Baden-Württemberg 69120, Germany
  • Medizinische Einrichtungen der Universität Bonn
    Bonn, Nordrhein-Westfalen 53105, Germany
  • SocraTec R&D GmbH
    Erfurt, Thüringen 99084, Germany
  • Charité - Campus Virchow-Klinikum (CVK)
    Berlin, 13353, Germany
  • Universitätsklinikum Hamburg Eppendorf (UKE)
    Hamburg, 20246, Germany
08

References and documents

Publications

  • Boettcher M, Mikus G, Trenk D, Dungen HD, Donath F, Werner N, Karakas M, Besche N, Schulz-Burck D, Gerrits M, Hung J, Becker C. Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study. Clin Transl Sci. 2022 May;15(5):1204-1214. doi: 10.1111/cts.13238. Epub 2022 Mar 17. PubMed 35299288 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Feb 2018, 5 months.

Of 33 phase 1 interventional studies under Coronary Artery Disease, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2017
First posted
Aug 21, 2017
StartActual
Aug 17, 2017
Primary completionActual
Feb 7, 2018
CompletionActual
Mar 23, 2018
Last update
Dec 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03255512
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
Aug 17, 2017
Primary completion
Feb 7, 2018
Completion
Mar 23, 2018
Last update
Dec 29, 2021

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vericiguat · Isosorbide mononitrate

Start the discussion